Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flamboyant 200/12 in Adults With Severe Asthma
NCT04191447Phase 3Unknown
- Sponsor
- EMS
- Start
- Jul 2022
- Primary completion
- Jul 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone propionate and formoterol in asthma (2 arms), sponsored by EMS. Primary endpoint: Forced expiratory volume in 1 second at 12 weeks. Status: unknown.
02
Drugs
fluticasone propionateformoterol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04191447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04191447.